Akeso biopharma (hkg: 09926)
Akeso Biopharma (HKG: 09926) is a biopharmaceutical company engaged in the research, development, production, and commercialization of innovative therapies, with a pipeline of over 30 drugs targeting various diseases, including cancers and autoimmune disorders.
Akeso biopharma (hkg: 09926) Overview
Akeso biopharma (hkg: 09926) Funding Rounds
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | 4/24/2020 | ||||
| Series E | 4/14/2020 | ||||
| Series D | 11/2/2019 | ||||
| Series C | 10/30/2018 | ||||
| Series B | 8/29/2017 | ||||
Series A | 7/1/2015 |
Akeso biopharma (hkg: 09926) Investors
| Investor | Investment Rounds | Lead Partner | Initial Investment | Other Notable Investments |
|---|---|---|---|---|
| Loyal Valley Capital | Series D | Series D (2019-11-02) | ||
| Fidelity Investments | Series E | Series E (2020-04-14) |
Akeso biopharma (hkg: 09926) 409a Valuations
| Date | Price per share | Est. Valuation | Filling |
|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Akeso biopharma (hkg: 09926) Filings
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
